Introduction
============

Being the most common cause of dementia, AD is a polygenic and neurodegenerative disease, defined as the presence of extracellular amyloid plaques and intracellular neurofibrillary tangles ([@B97]). Neuroinflammation, synaptic and neurotransmitter loss are also involved in the pathogenesis of AD ([@B46]; [@B5]). Clinically, patients' increasingly loss of memory and impairment of related cognitive functions is the main feature of AD, which can be further divided into two subtypes, the early onset and late-onset forms, based on the on-set age. ([@B99]).

Early-onset AD (EOAD) is usually autosomal dominant inherited, constituting barely 1--2% of AD, with genes including *amyloid precursor protein (APP), presenilin 1 (PSEN1)*, and *presenilin 2 (PSEN2)* being regarded as major factors ([@B99]; [@B4]). Although, late-onset AD (LOAD) is epidemiologically more common compared to EOAD, it is much more complex genetically because of the involvement of genetic, epigenetic and environmental factors. The *apolipoprotein E* (*APOE*) 𝜀4 allele is the first discovered genetic risk factor for LOAD ([@B75]). Thereafter, with the advent of the genome-wide association studies (GWASs), dozens of additional genes have been found as potential risk factors for LOAD. This long gene list has already included *ABCA7, BIN1, CASS4, CD2AP, CD33, CELF1, CLU, CR1, DSG2, EPHA1, FERMT2, HLA-DRB5/DRB1, INPP5D, MEF2C, MS4A4*/*MS4A6E, NME8, PICALM, PTK2B, SLC24A4*/*RIN3, SORL1, ZCWPW1* ([@B38]; [@B66]; [@B108]; [@B44]; [@B86]; [@B67]; [@B27]), with novel identified genes, such as *TREM2* and *PLD3* which might be involved in LOAD, continuously being added ([@B37]; [@B51]; [@B24]). The discovery of these genes has facilitated our gaining of the in-depth knowledge of the signaling pathways participated in AD pathogenesis. In this review, we will analyze functions of these genes and summarize possible mechanisms of how these genes would be involved in the pathogenesis of AD.

Early-Onset Alzheimer's Disease (EOAD)
--------------------------------------

### Amyloid β (Aβ) Metabolism

Highly penetrant mutations in *APP, PSEN1, PSEN2*, cause the autosomal dominant EOAD ([@B99]; [@B4]). Additionally, rare variants in *APP, PSEN1, PSEN2* ([@B23]), and *ADAM10* ([@B55]), have been listed as the risk factors for LOAD ([@B91]). These studies indicated that the disturbance of Aβ metabolism plays a central role in AD pathogenesis.

### APP

The *APP* gene is located on chromosome 21 and contains 19 exons for encoding a ubiquitously expressed type I transmembrane protein amyloid precursor protein (APP) ([@B35]). The amyloidogenic pathway and non-amyloidogenic pathway are the two mutually exclusively pathways thought to be involved. The amyloidogenic pathway is defined as consecutive cleavage of APP by β- and γ-secretase. Aβ, soluble APP ectodomain (sAPPβ) and the APP intracellular domain (AICD) are the generated products ([@B88]; [@B143]). Alternatively, α- and γ-secretase are engaged in the non-amyloidogenic pathway. Soluble APP ectodomain (sAPPα), p3-peptide and AICD are the end-products ([@B88]; [@B143]).

[@B34] first discovered a missense mutation in *APP* in AD pedigrees. At least 40 *APP* mutations are known to cause familial AD, mainly with an autosomal dominant inheritance pattern^[1](#fn01){ref-type="fn"}^. Two recessive mutations in *APP*, E693Δ and A673V, were also identified to cause EOAD ([@B26]; [@B33]). Most of these mutations are found in the neighborhood of the Aβ domain (exons 16 and 17 of *APP*). The Swedish *APP* mutation (KM670/671NL) lies at the N-terminus of the Aβ domain and increases plasma Aβ levels by 2 to 3-fold by affecting the efficiency of β-secretase cleavage ([@B85]). A sensible hypothesis is that excessive production of Aβ surpassing a certain threshold may cause AD. A supporting phenomenon is that Down syndrome patients, who have an extra copy of *APP* due to the 21 chromosome triplet, usually develop AD in their early life ([@B141]). Other *APP* mutations cluster at or after the C-terminal amino acids of the Aβ domain, such as the Flemish mutation (A692G) ([@B41]), Italian mutation (E693K) ([@B145]), Dutch mutation (E693Q) ([@B72]), Arctic mutation (E693G) ([@B52]), and Iowa mutation (D694N) ([@B36]), Iranian mutation (T714A) ([@B92]), Australian mutation (T714I) ([@B64]; [@B14]), French mutation (V715M) ([@B6]; [@B14]), German mutation (V715I) ([@B25]), Florida mutation (I716V) ([@B31]), and London mutation (V717I) ([@B34]). One thing these mutations may have in common is that they could produce more Aβ42 while decreasing the production of Aβ40 by affecting the cleaving activity of γ-secretase. Since Aβ42 is more amyloidogenic and easier to aggregate than Aβ40, patients with such *APP* mutations are more susceptible to AD, although their total amount of Aβ seems to be at the normal level. The Arctic mutation, E693G, affects neither the total Aβ amount nor the ratio of Aβ42 to Aβ40 ([@B52]). However, this mutation increases the aggregation rate of the mutant peptide. These findings altogether indicate Aβ aggregation plays a key role in AD pathogenesis.

### *PSEN1* and *PSEN2*

*PSEN1* and *PSEN2* are located at chromosome 14q24.3 and 1q31-q42, respectively, encoding the presenilin 1 and presenilin 2 proteins, which are participated in the formation of γ-secretase complex ([@B118]). In 1995, the first batch of mutations of the two genes were identified by researchers in EOAD families ([@B71]; [@B101]; [@B110]). To date, 219 different *PSEN1* mutations and 16 *PSEN2* mutations have been identified in association with EOAD^1^. *PSEN1* mutations account for 80% of the early-onset familial AD (EOFAD) cases, with *PSEN2* mutations found in 5% EOFAD families^1^.

In the APP cleavage scenario, endoproteolysis at the C-terminal end followed by a second cleavage at the N-terminal end of the Aβ domain was executed by the γ-secretase, resulting in the generation of Aβ fragments ([@B88]; [@B143]). Normally, most of the Aβ fragments are the less amyloidogenic Aβ40, Aβ42 occupies a small percentage. In contrast, the mutant γ-secretase would predominantly yield Aβ42 with small amount of Aβ40. Similar to what we have described for *APP* mutations, patients baring mutations of *PSEN1* or *PSEN2* might also be more susceptible to AD due to accumulation of the more amyloidogenic protein Aβ42 ([@B10]).

### ADAM10

Recently, having worked through 1000 LOAD families, researchers found, Q170H and R181G, in 7 pedigrees of them ([@B55]). *ADAM10* gene is located at chromosome 15q21.3, and encodes the AMAD10 protein, which is a member of the disintegrin and metalloprotease family ([@B103]). ADAM10 has been shown not only be able to readjust the constitutive activity of α-secretase, but to be responsible for accommodation of the regulatable activity of α-secretase in APP cleavage ([@B68]; [@B76]; [@B103]). Both Q170H and R181G mutations reside in the ADAM10 prodomain and significantly damage the cleavage ability of ADAM10 at the β-secretase site of APP both *in vitro* and *in vivo* ([@B55]). These findings further support the hypothesis that alteration of APP processing and Aβ generation is sufficient to cause AD.

Since Aβ peptides were discovered as a major pathological feature in AD brains, the hypothesis that excessive accumulation of misfolded β-sheet proteins causes AD started to gain public recognition. More and more evidence highlighted by genetic studies has been reported to support the central role that Aβ played in the pathogenesis of AD. For example, highly penetrant mutations have been identified as risk factors of AD in genes whose translation products are involved in APP processing and Aβ generation. Mutated genes such as *APP, PSEN1*, and *PSEN2* are thought to contribute to the pathogenesis of EOAD, while rare variants in *ADAM10* may increase the risk of developing LOAD. Given Aβ production was affected by mutations or variants in these genes, these findings further strengthened causal relationship between Aβ generation and AD pathogenesis (**Figure [1](#F1){ref-type="fig"}**).

![Schematic of APP processing pathways that are either amyloidogenic or non-amyloidogenic. The site of action of various AD-associated mutations are listed in the orange colored boxes.](fnmol-10-00319-g001){#F1}

Late-Onset for Alzheimer's Disease (LOAD)
-----------------------------------------

### Cholesterol Metabolism

The *APOE* 𝜀4 allele has been identified as a main risk factor for LOAD ([@B84]). The encoded protein apolipoprotein E (ApoE) plays the role as a cholesterol carrier in the brain. This implicates the role of cholesterol metabolism pathway in AD pathogenesis. Additionally, GWAS studies have identified several genes that might be potential risk factors for LOAD, including *ABCA7, CLU*, and *SORL1* ([@B38]; [@B66]; [@B44]; [@B67]; [@B27]), which are involved in cholesterol metabolism.

### APOE

The *APOE* is a gene situated in chromosome 19q13.2 encoding a protein containing 299 amino acids which is mainly expressed in the liver and brain ([@B114]). APOE is a key component of the lipoprotein complexes and plays a role in cholesterol metabolism by regulating cholesterol transport, delivery and distribution ([@B79]; [@B66]; [@B3]). *𝜀2, 𝜀3*, and *𝜀4* are the are three common alleles of *APOE* in humans differed in sequence by two single nucleotide polymorphisms, rs429358 and rs7412 (amino-acid position 112 and 158) in exon 4 ([@B75]; [@B84]). *APOE 𝜀3* allele is the most frequent isoform and accounts for 50--90% in all populations ([@B79]; [@B3]). The percentage of individuals having the *APOE 𝜀4* allele is approximately 50% in LOAD patients compared with 20--25% in controls ([@B3]; [@B84]). *So far APOE 𝜀4* is the most well-established genetic risk factor for both sporadic LOAD and familial AD in different populations ([@B39]; [@B96]; [@B32]). Compared with controls having no *𝜀4* alleles, the risk of AD is 4 times higher when subjects bearing one copy of the *𝜀4* allele, and 12 times higher with two copies ([@B3]). Conversely, the lower prevalence of the *𝜀2* allele in AD individuals compared with controls implicates its protective role in AD ([@B3]; [@B84]). In addition, the *APOE 𝜀4* allele can affect clinical diagnosis of AD by influencing MRI features except white matter lesion volume ([@B13]).

The mechanism of *APOE* increasing AD risk is not well known. The different APOE isoforms have different effects on Aβ aggregation and clearance in AD pathogenesis ([@B18]). Clearance of Aβ in the brain depends on coordination with APOE ([@B136]; [@B130]). Specifically, types of APOE that Aβ bound to affect its transportation efficiency. Aβ being bound to APOE2 or APOE3 results in better efficiency compared to APOE4 ([@B136]). APOE4 can also participate in other pathways, such as neuronal glucose hypometabolism, mitochondrial abnormalities and oxidative stress, by which play an important role in AD pathogenesis ([@B75]; [@B45]).

### ABCA7

*ABCA7* is a gene situated in chromosome 19p13.3 encoding ATP-binding cassette transporter A7 (ABCA7) which is a member of the ABC superfamily ([@B57]). The protein is highly expressed in the brain and functions as a transporter in the biogenesis of HDL by working together with cellular lipid and helical apolipoproteins ([@B123]). Data from several GWAS studies indicate *ABCA7* is a genetic risk factor for LOAD ([@B44]; [@B67]). According to a meta-analysis published on the AlzGene website in April, 2011^[2](#fn02){ref-type="fn"}^, a positive association between *ABCA7* rs3764650 and AD was found in total 31011 cases and 48354 controls in all populations. Additionally, several other genetic studies further confirmed the relevance between *ABCA7* SNPs and methylation changes with AD ([@B140]).

Loss of *ABCA7* in mice is not embryonic lethal, suggesting that ABCA7 is not essential ([@B56]). However, loss of ABCA7 in mice seems to impair the ability of bone marrow-derived macrophages to uptake oliomeric Aβ. A recent study further showed that crossing between *ABCA7*-deficient and transgenic amyloidogenic mice would double the insoluble Aβ levels and amyloid plaques in the brains of their progenies compared with controls ([@B73]). These findings indicate that ABCA7 may participate in the regulation of Aβ homoeostasis in the brain.

### CLU

The *CLU* gene is located at 8p21.1 and encodes a multifunctional chaperone protein, clusterin ([@B137]), which has been implicated in AD for the past 20 years ([@B82]; [@B89]; [@B17]). Clusterin, also meaning as apolipoprotein J (APOJ), is one of the major apolipoproteins, with upregulated expression in the cortex and hippocampus of AD patients ([@B82]; [@B89]; [@B93]). In terms of cholesterol metabolism, clusterin takes part in reverse cholesterol transport as a component of HDL particles ([@B136]). In addition, clusterin levels have been shown to be elevated in AD plasma ([@B50]). Meta analysis show that SNPs rs11136000, rs2279590, rs7012010, rs7982, and rs9331888 in *CLU* are protective genetic factors in LOAD^[3](#fn03){ref-type="fn"}^. However, the reproducibility of these associations was questionable when ethnic factors were taken into account ([@B74]; [@B61]; [@B121]). Genetic heterogeneity may be the underlying cause at play. Clusterin has several functions similar to apolipoprotein E and there are some interactions between them ([@B136]). Clusterin can also bind Aβ and modulate Aβ metabolism which are influenced by the molar ratios of clusterin and Aβ. ([@B139]; [@B1]). In addition, clusterin participates in cell apoptosis and complement regulation, lipid transport and membrane protection, thus plays a role in AD pathogenesis ([@B11]; [@B87]; [@B136]; [@B81]).

### SORL1

The *SORL1* gene, also known as *SORLA1* or *LR11*, is situated in 11q23.2--q24.2 and encodes the sortilin-related receptor containing LDL receptor class A repeats ([@B136]). SORL1 is a member of the VPS10 receptors family which functions by binding lipoproteins including APOE-containing particles, thus mediating endocytotic uptake ([@B134]; [@B136]). The decreased SORL1 expression was found to be associated with AD in 10 years ago ([@B106]). Utilizing microarray screening and immunohistochemistry, researchers showed that AD patients tend to have moderately lower *SORL1* DNA transcription levels in their lymphoblast and significantly decreased SORL1 protein level in their brains, especially the pyramidal neurons and frontal cortex ([@B106]). The suppression of SORL1 expression can lead to overexpression of Aβ and an increased risk of AD ([@B7]; [@B90]; [@B129]). In addition, two specific clusters of SNPs in *SORL1* were identified to have an association with familial and sporadic AD ([@B12]; [@B70]; [@B59]; [@B120]; [@B119]; [@B98]).

Since cholesterol is an integral component of biomembrane, due to the key roles of biomembrane in transportation and cleavage of APP, aggregation of Aβ, and Aβ toxicity, it is entirely possible that abnormality of cholesterol metabolism may have an impact on multiple links of the pathogenic signaling pathways of AD. Epidemiological studies showed that high cholesterol levels in mid-life may lead to dementia in later life. Cholesterol-lowering reagents, such as 3-hydroxy-3-methylglutaryl-coenzym, which is a reductase inhibitor known as statins, may reduce the likelihood of developing dementia. The APOE plays an indispensable role in cholesterol transport of the brain. As a risk factor of AD, the *APOE* gene bridges the gap between AD pathogenesis and cholesterol metabolism. This bridge was further reinforced when recent GWAS studies showed a new batch of genes, including *ABCA7, CLU*, and *SORL1*, may increase the risk of LOAD by affecting cholesterol metabolism.

Cell Adhesion and Endocytosis
=============================

Endocytosis is central to AD because APP, Aβ, and APOE are all internalized through the endolysosomal trafficking pathway, and alterations in APP trafficking through intracellular compartments can directly influence APP proteolytical cleavage ([@B46]). Several genes identified in GWAS-LOAD studies are associated with cell adhesion and endocytosis, including *BIN1, CD2AP, EPHA1, PICALM*, and *SORL1* ([@B38]; [@B44]; [@B86]; [@B67]; [@B144]).

BIN1
----

The *Bridging Integrator 1* (*BIN1*) is located on chromosome 2q14.3 and has 20 exons which can be spliced into multiple isoforms ([@B91]; [@B95]). BIN1 isoforms, such as isoforms 1--6, are mainly expressed in the brain, in neurons ([@B95]). BIN1 was initially found as a tumor suppressor with a MYC-interacting domain, a C-terminal SH3 domain, and an N-terminal BAR (Bin1/Amphiphysin/RVS167) domain ([@B104]). Processing diverse cellular functions, BIN1 is a key regulator within a cell. From endocytosis to membrane recycling, from cell cycle progression to apoptosis, we can see its roles ([@B95]). Cytoskeleton regulation and DNA repair are also involved ([@B95]).

*BIN1* was regarded as the second most important genetic risk factor for LOAD after the *APOE 𝜀4*.^[4](#fn04){ref-type="fn"}^ Common variants in the *BIN1* gene are initially identified to be associated with AD in GWAS-LOAD studies ([@B38]; [@B108]; [@B86]). The main associated SNPs are in the 5′ region, including the most significant SNPs rs744373 and rs7561528, which are located approximately 30 and 25 kb from the *BIN1* coding region, respectively ([@B38]; [@B108]; [@B86]; [@B53]). BIN1 can interact with cytoplasmic linker protein 170 (CLIP-170), a microtubule-associated protein ([@B83]). Genetic variants in *BIN1* were associated with magnetic resonance imaging measures associated with AD including entorhinal cortex thickness and temporal pole cortex thickness ([@B13]). Recent studies have demonstrated the physical interaction between BIN1 and tau protein in human neuroblastoma cells overexpressing these two proteins and in wild type mouse brain homogenates ([@B60]). Besides its potential effects on tau pathology, BIN1 has also been identified as a regulator of endocytosis and trafficking, immunity and inflammation of the brain, transient calcium potentials, and apoptosis ([@B122]).

CD2AP
-----

*CD2AP* (CD2-associated protein) is located on chromosome 6q12. CD2AP is first discovered as a ligand protein interacting with the T-cell-adhesion protein CD2 ([@B30]; [@B135]). CD2AP is widely expressed, primarily in epithelial and lymphoid cells ([@B111]). It consists of three N-terminal SH3 domains followed by a proline rich domain (PRD) and a C-terminal coiled-coil domain ([@B111]). CD2AP has been shown to be involved in signal transduction, podocyte homeostasis and dynamic actin remodeling ([@B78]). The protein also takes part in membrane trafficking during endocytosis and cytokinesis ([@B78]). SNPs rs9296559 and rs9349407 in *CD2AP* are associated with increased LOAD risk ([@B44]; [@B86]; [@B19]). Like *PICALM*, the homologs of *CD2AP* have shown to be able to suppress the Aβ toxicity in yeast and *Caenorhabditis elegans* ([@B126]). In addition, RNA interference-mediated disruption of *cindr*, the fly ortholog of *CD2AP*, enhances Tau toxicity in Drosophila ([@B112]).

EPHA1
-----

*EPHA1* (EPH Receptor A1) is a gene situated in chromosome 7q34. The encoded EPH Receptor A1 protein is a member of the ephrin family of tyrosine kinase receptors. Proteins of this family modulate cell adhesion by interacting with ephrin ligands on adjacent cells ([@B109]). Ephrin receptors also plays a role in regulating synapse formation and synaptic plasticity ([@B65]). In addition, these ephrin receptors participate in regulating apoptosis of neural progenitor cells ([@B63]; [@B58]). The SNP rs11771145 was identified as a protective genetic factor for LOAD ([@B44]; [@B86]; [@B19]). Albeit some research has been made on the function of ephrin receptors, knowledge on the *EPHA1* gene and its role in AD etiology remains to be lacking.

PICALM
------

*PICALM* (phosphatidylinositol binding clathrin assembly protein) is a gene situated in 11q14.2, encoding a clathrin adaptor protein which is produced as two main isoforms with 19--21 exons and 7 different known splice variants. *PICALM* was first cloned as a gene fused with AF10 in acute myeloid leukemia ([@B28]; [@B8]). Whereas *PICALM* is ubiquitously expressed, its homolog *AP180* is exclusively expressed in neuron ([@B138]). PICALM is implicated in clathrin mediated endocytosis and intracellular trafficking of the synaptic vesicle protein VAMP2 which is necessary for neurotransmitter release at the presynaptic membrane ([@B124]; [@B107]). Two SNPs (rs3851179 and rs541458) 5′ to the *PICALM* gene were identified to be associated with reduced LOAD risk in Caucasians ([@B38]; [@B66]; [@B67]). However, the reproducibility of these results was questionable when ethnic factor was taken into account ([@B74]; [@B61]; [@B121]). Genetic heterogeneity may be the underlying reason at play. In addition, AD patients with *PICALM* mutants may manifest different imaging features on MRI ([@B13]). Hippocampal volume and entorhinal cortex thickness are the two measures affected most prominently ([@B13]). Till now, the role of PICALM in AD etiology has not been known. The *YAP1802*, ortholog of *PICALM*, was found as a modifier of Aβ toxicity in a genome-wide screen in yeast ([@B126]; [@B8]). PICALM was also shown to have a protective role for C. elegans and rat cortical neurons against the toxicity of oligomeric Aβ ([@B126]). Another finding was that along with adaptor protein 2 (AP2) and APP-CTF, PICALM would be targeted to the autophagosomes to take part in the clearance of APP-CTF ([@B125]). In other words, PICALM may have a functional role in the clearance of Aβ via autophagy ([@B125]). In addition, PICALM displayed a specifically co-localization with neurofibrillary tangles in AD cases, suggesting that PICALM may participate in AD tau pathology ([@B8]).

Endocytosis is an active transportation mechanism to engulf molecules into a cell via vesicles formed by the cell membrane. It is the basis of various neuronal physiological functions, including synaptic vesicle transport and neurotransmitter release. The transportation and amyloidogenic cleavage of APP are interacting with the endocytosis pathway within cells. Thus, abnormal alterations in endocytosis may contribute to AD pathogenesis. Based on this hypothesis, SNPs in genes related to cell adhesion and endocytosis, such as *BIN1, CD2AP, EPHA1, PICALM*, and *SORL1* are very likely to be involved in AD pathogenesis.

Immune Response
===============

Neuroinflammation is a hallmark of AD ([@B42]). Solid evidence have proven the activation of inflammatory pathways in AD pathogenesis ([@B42]; [@B144]). Common variants in *ABCA7, CD33, CLU, CR1, EPHA1, HLA-DRB5/DRB1, INPP5D, MEF2C*, and *MS4A*, have been found to be associated with immune responses in recent GWAS studies ([@B38]; [@B66]; [@B108]; [@B44]; [@B86]; [@B67]). Additionally, rare coding variants in *TREM2* gene related to the immune response were identified to increase risk of AD in LOAD ([@B37]; [@B51]).

CD33
----

*CD33* is located on chromosome 19q13.3 and encodes a transmembrane glycoprotein cluster of differentiation 33 (CD33) ([@B142]). CD33, which belongs to the sialic acid-binding immunoglobulin-like lectins (Siglecs) family, bears molecular features of immune cell surface receptors that could trigger immune cell--cell interactions ([@B132]). Studies showed that the expression of CD33 was increased in AD brains ([@B54]). The rs3865444 in *CD33* was reported to be linked to a lowered LOAD risk ([@B44]; [@B86]). The rs3865444 A allele is associated with the decreased overall CD33 expression and an increased proportion of the CD33 isoform lacking exon 2 ([@B80]). The exon 2 in *CD33* codes the IgV domain which mediates Siglecs family members binding to sialic acid, resulting in inhibition of phagocytosis ([@B131]). Loss of exon2 of CD33 in microglia abolishes the inhibitory effect of Aβ phagocytosis ([@B80]). In the context of the rs3865444 risk allele, there are increased cell surface expression of CD33 in monocytes, decreased internalization of Aβ42 accumulation in neuritic and fibrillar amyloid pathology, and more microglias activated ([@B16]). Thus, CD33 may play an important role in Aβ clearance mediated by microglia in AD brain.

CR1
---

*CR1* (Complement receptor 1) is located on chromosome 1q32 and encodes a multifunctional glycoprotein, expressed on microglia and blood cells such as erythrocytes ([@B131]). CR1 is a cell surface receptor that has binding sites for complement factors C3b and C4b. It participates in the clearance of immune complexes and regulates complement activation ([@B29]). Two SNPs (rs6656401 and rs3818361) in *CR1* have been found to be associated with LOAD risk in most Caucasians ([@B66]). These associations could not be reproduced in other ethnic groups including African American, Israeli-Arab, Caribbean Hispanic, and Polish individuals due to the genetic heterogeneity ([@B74]; [@B61]; [@B121]). Genetic variants in *CR1* can affect magnetic resonance imaging measures associated with AD such as entorhinal cortex thickness ([@B13]). The exact function of CR1 in AD pathogenesis remains to be elusive. Since Aβ oligomers can bind C3b, some researchers postulated that CR1 may take part in the clearance of Aβ ([@B22]).

HLA-DRB5/DRB1
-------------

The *HLA-DRB5/DRB1* locus is a highly polymorphic region located on chromosome 6, encoding a member of the major histocompatibility complex class II (MHC II), which is involved in the immune response and histocompatibility ([@B127]; [@B131]). Recently, *HLA-DRB5/DRB1* has been shown to be associated with multiple sclerosis and Parkinson's disease (PD) ([@B47]; [@B48]). Although PD and AD have distinct etiologies, they are both characterized by neurodegeneration resulting from abnormal protein aggregation. Therefore, it is a distinct possibility that HLA genes may play a similar role in both PD and AD through regulating inflammatory responses.

INPP5D
------

The *INPP5D* gene is a gene situated in chromosome 2q37.1, encoding a 145 kD protein which is a member of the inositol polyphosphate-5-phosphatase (INPP5) family, also known as SH2 domain containing inositol-50-phosphatase 1 (SHIP1) ([@B9]; [@B144]). INPP5D is expressed predominantly in the hematopoietic cells ([@B40]; [@B9]; [@B144]). On the cell membrane, the protein takes part in various signaling pathways by hydrolyzing the 5′ phosphate from phosphatidylinositol (3,4,5)-trisphosphate and inositol-1,3,4,5-tetrakisphosphate ([@B105]). Also, INPP5D plays as a negative regulator in B cell proliferation, chemotaxis and activation, as well as IgE- or IgE + Ag-induced inflammatory cytokine release from mast cells ([@B116], [@B115]; [@B144]). More studies are needed to understand the mechanism of how SHIP regulates the immune response and inflammation in the brain.

MEF2C
-----

MEF2C protein is widely expressed and belongs to the MADS box transcription enhancer factor 2 (MEF2) family of transcription factors. The *MEF2C* gene is located on chromosome 5q14.3. It has been reported that MEF2 acts as a central transcriptional component of the innate immune response in the adult fly ([@B20]). Therefore, it is possible that MEF2C is involved in the inflammatory process in AD brains.

MS4A
----

The *MS4A* locus is located on chromosome 11 and contains at least five genes implicated in immune modulation ([@B131]). The discovery of the MS4A family owes to their homology to CD20, a B-lymphocyte cell surface molecule. Members of the MS4A family, including MS4A6A, are factors affecting AD pathology ([@B94]). Variations in proxies of rs670139 can increase AD risk ([@B2]).

TREM2
-----

The *TREM2* gene maps to chromosome 6p21.1, encoding Triggering Receptor Expressed on Myeloid Cells 2 (TREM2). TREM2 is mainly expressed on myeloid cells ([@B21]; [@B49]). In the brain, TREM2 is primarily expressed on microglia ([@B77]). TREM2 takes part in inflammatory responses regulation ([@B102]).

Homozygous mutations in *TREM2* gene cause Nasu--Hakola disease, characterized by early onset frontotemporal-like dementia and bone involvement ([@B62]). In addition, some families with FTD-like dementia with leukodystrophy but without bone involvement have homozygous *TREM2* mutations ([@B37]). Recently, rare variants of the *TREM2* gene have been identified to increase susceptibility to LOAD with an odds ratio similar to that of *APOE 𝜀4* ([@B15]). rs75932628 is the most common variant in *TREM2* polymorphism. It replaces Arginine 47 with Histidine and causes a 3-fold increase in the susceptibility to LOAD ([@B37]; [@B51]; [@B144]). The status of *TREM2* as a major LOAD risk locus was further strengthened by the odds ratio of 3.4 reported in a meta analysis ([@B37]). The exact functions of TREM2 are not well understood. TREM2 may affect AD pathology through regulating phagocytosis ([@B43]). The expression levels of TREM2 are upregulated in microglia found at the border of amyloid plaque deposits in transgenic AD mice ([@B77]). Moreover, there was a positive correlation between TREM2 expression and the phagocytic clearance of Aβ in APP transgenic mice ([@B77]).

Increasing evidence suggests the activation of inflammatory pathways in AD pathogenesis. GWAS suggests that several genes (*ABCA7, CD33, CLU, CR1, EPHA1, HLA-DRB5/DRB1, INPP5D, MEF2C*, and *MS4A*) regulating clearance of misfolded proteins mediated by glia and the inflammatory reaction could increase the risk of AD in LOAD. Furthermore, a rare variant of the *TREM2* gene, with an odds ratio similar to that of *APOE 𝜀4*, was recently identified to be able to increase patients' susceptibility to LOAD. These results together argue for the point that neuroinflammation is associated with AD pathogenesis. Although there is a lack of understanding how inflammation in AD is affected by these genes, the discovery of them have broadened our knowledge scope of AD and may expedite the unraveling of new therapeutic targets for the prevention and treatment of AD.

Tau Metabolism
==============

The microtubule-associated protein tau is integral to the pathogenesis of AD. Rare mutations in the *MAPT* gene cause familial dementia syndromes ([@B69]). GWAS studies have identified several genes that might be potential risk factors for LOAD, including *BIN1, CD2AP, CELF1, FERMT2* and *PICALM*, which are involved in modulating tau neurotoxicity ([@B38]; [@B108]; [@B44]; [@B86]; [@B67]).

CELF1
-----

The *CELF1* gene is located on chromosome 11p11.2 and encodes the CUGBP and Elav-like family member 1 protein (CELF1). Members of the CELF protein family regulate alternative splicing, editing, and translation of mRNA ([@B133]). *CELF1* gene may have a role in myotonic dystrophy type 1 (DM1) because of its interactions with the dystrophia myotonica-protein kinase (DMPK) gene ([@B100]). In addition, overexpression of *CELF1* suppressed the neurodegenerative eye phenotype in a transgenic fly model of fragile X-associated tremor/ataxia syndrome (FXTAS) ([@B117]). The CELF1 protein modulates rCGG-mediated toxicity via a specific interaction with hnRNP A2/B1 ([@B117]). Like *FERMT2*, RNA interference-mediated disruption of *aret*, the fly ortholog of *CELF1*, enhances Tau toxicity in a *Drosophila* model of AD ([@B112]).

FERMT2
------

The *FERMT2* (Fermitin Family Member 2) gene is located on chromosome 14q22 and is also known as mitogen-inducible gene 2 (*MIG2*) or kindlin 2 (*KIND2*) ([@B113]). FERMT2 is ubiquitously expressed in mammalian cells and functions as a kind of cell-extracellular matrix (ECM) structures ([@B128]). A recent research validated the association of *FERMT2* with AD risk by using a *Drosophila* model ([@B112]). RNA interference-mediated disruption of *FERMT2* homologs enhances Tau toxicity in Drosophila indicates these associations ([@B112]).

Comprising of hyper-phosphorylated and aggregated tau protein, NFTs are one of the major pathological signatures of the AD brain. The neurotoxicity of Tau plays a central role in AD pathogenesis by affecting Aβ metabolism. It has been shown that there was a causal relationship between certain mutations of either *APP* or *MAPT* and familial dementia syndromes. As more and more genes related to tau neurotoxicity were identified as risk genes of AD, hopefully the molecular basis between Tau toxicity and AD would gradually become clear.

Perspectives
============

Genome-wide association studies is a powerful tool in identifying putative genetic risk factors. To date, more than 20 genetic variants have been identified as risk factors of AD. There is no gainsaying that GWAS helps us find novel perspectives on the pathogenesis of AD. However, there are still some limitations to be scrutinized. Firstly, some of these AD-associated variants are too rare or too weak to be used as prognostic predictors, which to some extent confound the integration of potential pathophysiological pathways of AD. On the contrary, whole exome sequencing has also discovered rare variants, such as *TREM2* variants, whose odds ratios are comparable to that of *APOE 𝜀4* in terms of increasing the risk of AD. Therefore, the range of these variants seems to be overly wide, which may have made it difficult for us to form a coherent and integrated theory. Moreover, although both SNPs with minor allele frequency down to 1% and novel functional exonic variants have been incorporated into the latest version of GWAS arrays, the detection would still be problematic when it comes to variants not tagged by the known SNPs or some extremely rare structural variants whose minor allele frequency are less than 1%. However, the role of such rare and structural variants should not be negligible in complex disease like AD. Therefore, ongoing and future large-scale next-generation whole exome or whole genome sequencing techniques need to address the issues aforementioned to accurately target causative variants in regions identified by GWAS. For only truly causative variants could yield meaningful functional studies to dissect molecular pathways in AD pathogenesis (**Table [1](#T1){ref-type="table"}**).

###### 

Potential mechanisms of AD genes.

  Gene               SNP                                                   Chromosome position   Protein                                                             EOAD/ LOAD   Proposed function                                                                                                                        Implicated pathways
  ------------------ ----------------------------------------------------- --------------------- ------------------------------------------------------------------- ------------ ---------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------
  *ABCA7*            rs3764650 rs4147929                                   19p13.3               ATP-binding cassette transporter A7                                 LOAD         Lipid homeostasis                                                                                                                        Cholesterol metabolism; immune response
  *ADAM10*           rs61751103 rs145518263                                15q21.3               A disintegrin and metalloprotease family, AMAD10                    LOAD         Proteolytic cleavage of integral membrane proteins                                                                                       Aβ metabolism
  *APOE*             rs429358 rs7412                                       19q13.2               Apolipoprotein E                                                    LOAD         Mediates binding, internalization, and catabolism of lipoproteins                                                                        Cholesterol metabolism
  *APP*              --                                                    21q21.3               Amyloid precursor protein                                           EOAD         Neurite outgrowth, adhesion, and axonogenesis                                                                                            Aβ metabolism
  *BIN1*             rs744373 rs7561528                                    2q14                  Bridging Integrator 1                                               LOAD         Regulation of endocytosis of synaptic vesicles                                                                                           Cell adhesion and endocytosis; tau metabolism
  *CASS4*            rs7274581                                             20q13.31              Cas scaffolding protein family member 4                             LOAD         Docking protein in tyrosine-kinase signaling involved in cell adhesion and spreading                                                     Cytoskeleton and axonal transport
  *CD2AP*            rs9296559 rs9349407                                   6p12                  CD2-associated protein                                              LOAD         Scaffold molecule regulating actin cytoskeleton                                                                                          Cell adhesion and endocytosis; tau metabolism
  *CD33*             rs3865444                                             19q13.3               Cluster of differentiation 33                                       LOAD         Mediates sialic acid-dependent binding to cells                                                                                          Immune response
  *CELF1*            rs10838725                                            11p11                 CUGBP and Elav-like family member 1                                 LOAD         Regulates pre-mRNA splicing                                                                                                              Tau metabolism
  *CLU*              rs11136000, rs2279590, rs7012010, rs7982, rs9331888   8p21-p12              Clusterin                                                           LOAD         Chaperone; regulation of cell proliferation                                                                                              Cholesterol metabolism Immune response
  *CR1*              rs6656401 rs3818361                                   1q32                  Complement receptor 1                                               LOAD         Mediates cellular binding of immune complexes that activate complement                                                                   Immune response
  *DSG2*             rs8093731                                             18q12.1               Desmoglein 2                                                        LOAD         Mediates cell--cell junctions between epithelial and other cell type                                                                     Cytoskeleton and axonal transport
  *EPHA1*            rs11771145                                            7q34                  EPH Receptor A1                                                     LOAD         Brain and neural development; angiogenesis, cell proliferation, and apoptosis                                                            Cell adhesion and endocytosis; immune response
  *FERMT2*           rs17125944                                            14q22.1               Fermitin Family Member 2                                            LOAD         Actin assembly and cell shape and mediator of angiogenesis                                                                               Tau metabolism
  *HLA-DRB5/DRB1*    rs9271192                                             6p21.3                Major histocompatibility complex, class II, DR beta 5- DR beta 1    LOAD         Immunocompetence and histocompatibility                                                                                                  Immune response
  *INPP5D*           rs35349669                                            2q37.1                Inositol polyphosphate-5-phosphatase                                LOAD         Negative regulator of myeloid cell proliferation and survival                                                                            Immune response
  *MEF2C*            rs190982                                              5q14.3                Myocyte enhancer factor 2C                                          LOAD         Controls synapse formation                                                                                                               Immune response
  *MS4A4*/*MS4A6E*   rs983392 rs670139                                     11q12.1               Membrane-spanning 4-domains, subfamily A, member 4A/6E              LOAD         Signal transduction                                                                                                                      Immune response
  *NME8*             rs2718058                                             7p14.1                NME/NM23 family member 8                                            LOAD         Ciliary functions                                                                                                                        Cytoskeleton and axonal transport
  *PICALM*           rs3851179 rs541458                                    11q14                 Phosphatidylinositol binding clathrin assembly protein              LOAD         AP2-dependent clathrin-mediated endocytosis                                                                                              Cell adhesion and endocytosis; tau metabolism
  *PSEN1*            --                                                    14q24.3               Presenilin 1                                                        EOAD         Component of catalytic subunit of gamma-secretase complex                                                                                Aβ metabolism
  *PSEN2*            --                                                    1q31-q42              Presenilin 2                                                        EOAD         Component of catalytic subunit of gamma-secretase complex                                                                                Aβ metabolism
  *PTK2B*            rs28834970                                            8p21.1                Protein tyrosine kinase 2 beta                                      LOAD         Induction of long term potentiation in hippocampus                                                                                       Endocytosis
  *SLC24A4/RIN3*     rs10498633                                            14q32.12              Solute carrier family 24, member 4/ Ras and Rab interactor 3        LOAD         Brain and neural development                                                                                                             Neural development, synapse function, endocytosis
  *SORL1*            rs11218343                                            11q23.2-q24.2         Sortilin-related receptor containing LDL receptor class A repeats   LOAD         APOE receptor; binds LDL and RAP and mediates endocytosis of the lipids to which it binds                                                Cholesterol Metabolism; Cell adhesion and endocytosis
  *TREM2*            rs75932628                                            6p21.1                Triggering Receptor Expressed on Myeloid Cells 2                    LOAD         Induces phagocytosis of apoptotic neurons, and regulates Toll-like receptor mediated inflammatory responses, and microglial activation   Immune response
  *ZCWPW1*           rs1476679                                             7q22.1                Zinc finger, CW type with PWWP domain 1                             LOAD         Epigenetic regulation                                                                                                                    Epigenetic regulation

Conclusion
==========

AD is a complex disorder. What we have known is still a drop in the ocean. To improve the prevention and treatment strategies of AD, finding the potential genes in AD pathogenesis and their relationships is a necessary and essential step. It is the fundamental basis for the molecular diagnosis of AD and the mechanistic study on neurodegeneration. Current genetic findings indicated putative disease mechanisms including Aβ metabolism, cell adhesion and endocytosis, immune response, tau metabolism. Future GWASs or next generation sequencing (NGS) approaches studies would keep playing important roles in revealing promising therapeutic targets.

Author Contributions
====================

QS, RL, and YS discussed the concepts and wrote the manuscript. QS, NX, and BT revised the manuscript.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

This work was supported by the National Key Research and Development Program, Ministry of Science and Technology of China Grant No.2016YFC1300500-03 (to YS); National Institute on Aging Grant Nos.NIHR01AG032441-01 (to YS), NIHR21 AG049237 (to RL), and RO1AG025888 (to YS); Alzheimer's Association Zenith Award and Grant No. IIRG-07-59510 (to YS); American Health Assistance Foundation Grant No. G2006-118 (to RL); and National Natural Science Foundation of China Grant No. 81401059 (to QS).

<http://www.molgen.ua.ac.be/ADmutations>

[www.alzgene.org](http://www.alzgene.org)

<http://www.alzgene.org>

<http://www.alzgene.org/>

[^1]: Edited by: *Oliver Wirths, Universitätsmedizin Göttingen, Germany*

[^2]: Reviewed by: *Hong Qing, Beijing Institute of Technology, School of Life Sciences, China; Marcus O. Grimm, Saarland University, Germany*
